NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free CMPX Stock Alerts $1.98 -0.07 (-3.41%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.0450-Day Range$1.20▼$2.2952-Week Range$1.15▼$3.62Volume176,678 shsAverage Volume505,682 shsMarket Capitalization$272.43 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Compass Therapeutics alerts: Email Address Compass Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$9.00 Price TargetShort InterestHealthy2.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector477th out of 938 stocksBiological Products, Except Diagnostic Industry76th out of 148 stocks 3.5 Analyst's Opinion Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Compass Therapeutics has a forecasted upside of 354.5% from its current price of $1.98.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.29% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 2.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 2.9 News and Social Media Coverage News SentimentCompass Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Compass Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Compass Therapeutics Stock (NASDAQ:CMPX)Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More CMPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPX Stock News HeadlinesMarch 25, 2024 | markets.businessinsider.comCompass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic MilestonesMarch 24, 2024 | investorplace.com3 Penny Stocks With the Power to 10X Your $1K InvestmentMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 23, 2024 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Compass Therapeutics (NASDAQ:CMPX)March 22, 2024 | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Receives "Buy" Rating from HC WainwrightMarch 22, 2024 | markets.businessinsider.comCompass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy RatingMarch 21, 2024 | globenewswire.comCompass Therapeutics Reports 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | finance.yahoo.comWith 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 29, 2024 | globenewswire.comCompass Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | finance.yahoo.comCompass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical TrialFebruary 8, 2024 | msn.comCompass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should KnowFebruary 2, 2024 | morningstar.comCompass Therapeutics Inc Ordinary SharesJanuary 31, 2024 | finance.yahoo.comWe're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn RateJanuary 5, 2024 | finance.yahoo.comCompass Therapeutics Provides Corporate UpdateDecember 20, 2023 | finance.yahoo.comCompass Therapeutics Insider Ups Holding During YearNovember 17, 2023 | finance.yahoo.comCompass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 17, 2023 | finance.yahoo.comCompass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate DevelopmentsNovember 14, 2023 | msn.comCompass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 3, 2023 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)September 27, 2023 | theglobeandmail.comInstrument Name Compass Therapeutics Inc Instrument Symbol (CMPX-Q)August 24, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn SituationAugust 3, 2023 | msn.comHC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy RecommendationAugust 3, 2023 | msn.comCompass Therapeutics GAAP EPS of -$0.09August 3, 2023 | finance.yahoo.comCompass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 22, 2023 | msn.comCompass Therapeutics added to Russell indexesJune 22, 2023 | finance.yahoo.comCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesSee More Headlines Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.07% Return on Assets-24.49% Debt Debt-to-Equity RatioN/A Current Ratio19.73 Quick Ratio19.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.69Miscellaneous Outstanding Shares137,590,000Free Float96,312,000Market Cap$272.43 million OptionableNot Optionable Beta0.76 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Vered Bisker-Leib M.D. (Age 52)MBA, Ph.D., Chief Executive Officer Comp: $806.43kDr. Thomas J. Schuetz M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Vice Chair Comp: $829.56kMr. Neil L. Lerner CPA (Age 57)Vice President of Finance Mr. Jonathan Anderman J.D.VP, Head of Legal & Corporate SecretaryAnna GiffordCommunications ManagerDr. Minori Rosales M.D. (Age 61)Ph.D., Senior VP & Head of Clinical Development Ms. Karin Herrera B.A.VP & Head of Clinical OperationsDr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & ControlsMore ExecutivesKey CompetitorsScilexNASDAQ:SCLXGritstone bioNASDAQ:GRTSSutro BiopharmaNASDAQ:STROCentury TherapeuticsNASDAQ:IPSCThird Coast BancsharesNASDAQ:TCBXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 26,330 shares on 3/11/2024Ownership: 3.201%Goldman Sachs Group Inc.Sold 13,585 shares on 3/1/2024Ownership: 0.162%Virtu Financial LLCBought 28,054 shares on 2/26/2024Ownership: 0.022%Vanguard Group Inc.Sold 26,330 shares on 2/15/2024Ownership: 3.201%Legal & General Group PlcSold 25,324 shares on 2/15/2024Ownership: 0.017%View All Institutional Transactions CMPX Stock Analysis - Frequently Asked Questions Should I buy or sell Compass Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPX shares. View CMPX analyst ratings or view top-rated stocks. What is Compass Therapeutics' stock price target for 2024? 2 equities research analysts have issued 12-month price objectives for Compass Therapeutics' shares. Their CMPX share price targets range from $8.00 to $10.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 354.5% from the stock's current price. View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts. How have CMPX shares performed in 2024? Compass Therapeutics' stock was trading at $1.56 at the beginning of 2024. Since then, CMPX stock has increased by 26.9% and is now trading at $1.98. View the best growth stocks for 2024 here. When is Compass Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CMPX earnings forecast. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its earnings results on Thursday, November, 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Compass Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.20%), Vanguard Group Inc. (3.20%), Blue Owl Capital Holdings LP (2.22%), Northern Trust Corp (0.60%), Monashee Investment Management LLC (0.39%) and Braidwell LP (0.25%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMPX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.